What's Happening?
Signum Surgical, a medical technology company specializing in colorectal disorder treatments, has appointed Mark J. Foley as Chairman of the Board. Foley, a seasoned executive with over 30 years in the medical device industry, joins as the company expands
the commercial reach of its BioHealx® technology. This innovative device, which has received FDA De Novo 510(k) clearance, offers a minimally invasive treatment for anal fistulas, a condition affecting one in 5,000 people globally. The BioHealx® device has demonstrated an 84.4% success rate in clinical trials, providing a compelling alternative to traditional surgical methods. Foley's appointment is expected to bolster the company's growth and market presence.
Why It's Important?
The appointment of Mark J. Foley as Chairman is a strategic move for Signum Surgical as it seeks to enhance its market position and expand the adoption of its BioHealx® technology. Foley's extensive experience in scaling medical device companies is likely to drive the company's commercial success and innovation in colorectal care. The BioHealx® device addresses a significant unmet need in the treatment of anal fistulas, offering improved patient outcomes and quality of life. This development is crucial for the medical community and patients, as it provides a safer, more effective treatment option, potentially reducing healthcare costs and improving patient care standards.
